CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.
Hsp70
IL-2
activated NK cells
adoptive Immunotherapy
anti-Hsp70 CAR T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
02
2022
accepted:
02
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Strategies to boost anti-tumor immunity are urgently needed to treat therapy-resistant late-stage cancers, including colorectal cancers (CRCs). Cytokine stimulation and genetic modifications with chimeric antigen receptors (CAR) represent promising strategies to more specifically redirect anti-tumor activities of effector cells like natural killer (NK) and T cells. However, these approaches are critically dependent on tumor-specific antigens while circumventing the suppressive power of the solid tumor microenvironment and avoiding off-tumor toxicities. Previously, we have shown that the stress-inducible heat shock protein 70 (Hsp70) is frequently and specifically expressed on the cell surface of many different, highly aggressive tumors but not normal tissues. We could take advantage of tumors expressing Hsp70 on their membrane ('mHsp70') to attract and engage NK cells after
Identifiants
pubmed: 35720311
doi: 10.3389/fimmu.2022.883694
pmc: PMC9198541
doi:
Substances chimiques
HSP70 Heat-Shock Proteins
0
Interleukin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
883694Informations de copyright
Copyright © 2022 Bashiri Dezfouli, Yazdi, Benmebarek, Schwab, Michaelides, Miccichè, Geerts, Stangl, Klapproth, Wagner, Kobold and Multhoff.
Déclaration de conflit d'intérêts
GM. is the founder and Chief Scientific Officer of multimmune GmbH. SK has received honoraria from TCR2 Inc, Novartis, BMS and GSK. SK is an inventor of several patents in the field of immuno-oncology. SK received license fees from TCR2 Inc and Carina Biotech. SK received research support from TCR2 Inc. and Arcus Bio-science for work unrelated to the manuscript. AM and DG are employed by Glycostem Therapeutics BV. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Death Differ. 2005 Jan;12(1):38-51
pubmed: 15592361
Int Immunopharmacol. 2021 Sep;98:107836
pubmed: 34218217
Front Immunol. 2019 Mar 22;10:454
pubmed: 30967859
Leukemia. 2021 Aug;35(8):2243-2257
pubmed: 33414484
Stem Cell Rev Rep. 2019 Oct;15(5):619-636
pubmed: 31161552
JAMA. 2020 Sep 1;324(9):832
pubmed: 32870282
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Cancers (Basel). 2020 Nov 30;12(12):
pubmed: 33266177
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Nat Biomed Eng. 2021 Nov;5(11):1246-1260
pubmed: 34083764
Mol Ther. 2017 Nov 1;25(11):2452-2465
pubmed: 28807568
Front Oncol. 2019 Feb 11;9:51
pubmed: 30805309
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268
pubmed: 31217020
Biochem Cell Biol. 2019 Apr;97(2):85-90
pubmed: 30273495
Exp Hematol. 1999 Nov;27(11):1627-36
pubmed: 10560910
Cancer Res. 2006 Nov 15;66(22):10995-1004
pubmed: 17108138
Clin Cancer Res. 2004 Jun 1;10(11):3699-707
pubmed: 15173076
J Extracell Vesicles. 2020 May 20;9(1):1766192
pubmed: 32595915
Cells. 2020 May 09;9(5):
pubmed: 32397414
Cancers (Basel). 2021 Jul 27;13(15):
pubmed: 34359663
Front Immunol. 2016 Oct 27;7:454
pubmed: 27833611
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Blood. 2012 Jun 14;119(24):5688-96
pubmed: 22555974
Cancer Discov. 2018 Oct;8(10):1219-1226
pubmed: 30135176
Cell Stress Chaperones. 2001 Oct;6(4):337-44
pubmed: 11795470
Nat Commun. 2020 Jan 31;11(1):661
pubmed: 32005826
Blood Cancer J. 2021 Jun 4;11(6):108
pubmed: 34088894
Blood Adv. 2019 Jun 11;3(11):1681-1694
pubmed: 31167820
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):733-8
pubmed: 21187371
IUBMB Life. 2019 Dec;71(12):1834-1845
pubmed: 31441584
Clin Cancer Res. 2019 Mar 15;25(6):1702-1708
pubmed: 30413526
J Cancer. 2021 Jan 21;12(6):1804-1814
pubmed: 33613769
Cancers (Basel). 2021 Jul 23;13(15):
pubmed: 34359606
Front Immunol. 2018 Apr 16;9:737
pubmed: 29713323
Front Cell Dev Biol. 2021 Nov 10;9:750022
pubmed: 34858978
J Immunol. 1997 May 1;158(9):4341-50
pubmed: 9126997
Oncoimmunology. 2015 Jan 09;4(3):e991613
pubmed: 25949911
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
PLoS One. 2008 Apr 02;3(4):e1925
pubmed: 18382692
Front Immunol. 2017 Apr 26;8:458
pubmed: 28491060
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Biol Chem. 2018 Oct 12;293(41):15947-15961
pubmed: 30158244
Cell Stress Chaperones. 2008 Summer;13(2):221-30
pubmed: 18759005
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12
pubmed: 28975930
Semin Cancer Biol. 2020 Oct;65:80-90
pubmed: 31705998
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32544101
Front Immunol. 2016 Oct 10;7:413
pubmed: 27777574
Innate Immun. 2013 Feb;19(1):76-85
pubmed: 22781631
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
J Biol Chem. 2003 Oct 17;278(42):41173-81
pubmed: 12874291
Adv Exp Med Biol. 2020;1232:131-143
pubmed: 31893404
J Immunol. 2006 May 15;176(10):6270-6
pubmed: 16670338
Memo. 2021;14(2):143-149
pubmed: 34777609
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Nat Med. 2019 Sep;25(9):1408-1414
pubmed: 31477906
Hum Gene Ther. 2019 Apr;30(4):402-412
pubmed: 30693795
Cancer Cell. 2020 Oct 12;38(4):454-472
pubmed: 32822573
Clin Cancer Res. 2020 Oct 15;26(20):5368-5379
pubmed: 32873573
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Cytokine. 2019 May;117:30-40
pubmed: 30784898
Nat Rev Immunol. 2002 Oct;2(10):735-47
pubmed: 12360212
Cells. 2019 May 17;8(5):
pubmed: 31108883
Transl Oncol. 2021 Jul;14(7):101079
pubmed: 33862524
Cell Res. 2021 Nov;31(11):1190-1198
pubmed: 34376814
J Hematol Oncol. 2017 Mar 13;10(1):68
pubmed: 28288656
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Sci Adv. 2021 Jun 9;7(24):
pubmed: 34108220
Br J Cancer. 2019 Jan;120(1):26-37
pubmed: 30413825
J Natl Cancer Inst. 2014 Nov 24;107(1):364
pubmed: 25424197
Cancer Immunol Res. 2018 May;6(5):509-516
pubmed: 29615399
Int J Cancer. 1995 Apr 10;61(2):272-9
pubmed: 7705958
Front Immunol. 2018 Mar 08;9:441
pubmed: 29568297
Am J Cancer Res. 2019 Feb 01;9(2):228-241
pubmed: 30906625
Cancer Gene Ther. 2000 Jun;7(6):870-8
pubmed: 10880017
Cell Stress Chaperones. 2002 Oct;7(4):365-73
pubmed: 12653481
Mol Ther. 2021 Feb 3;29(2):788-803
pubmed: 33068779
Cancer. 2007 Aug 15;110(4):926-35
pubmed: 17580361
Sci China Life Sci. 2016 Apr;59(4):386-97
pubmed: 26961900
Annu Rev Immunol. 2001;19:197-223
pubmed: 11244035
Cells. 2021 Dec 01;10(12):
pubmed: 34943898
Leukemia. 2018 May;32(5):1157-1167
pubmed: 29479065
Cell Stress Chaperones. 2003 Winter;8(4):348-60
pubmed: 15115287
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875739
Am J Cancer Res. 2019 May 01;9(5):945-958
pubmed: 31218103
Cancers (Basel). 2018 Dec 28;11(1):
pubmed: 30597841
J Immunol. 2004 Jan 15;172(2):972-80
pubmed: 14707070
Biochem Biophys Res Commun. 2021 Jan 1;534:149-156
pubmed: 33309274
Clin Cancer Res. 2019 Oct 1;25(19):5890-5900
pubmed: 31285373
Int J Biochem Cell Biol. 2014 Apr;49:42-52
pubmed: 24440757
Cancer Immunol Immunother. 2019 Jun;68(6):1011-1024
pubmed: 31053876
Int J Cancer. 1998 Sep 11;77(6):942-8
pubmed: 9714069
Biol Chem. 2003 Feb;384(2):267-79
pubmed: 12675520
Front Immunol. 2018 Jan 17;8:1976
pubmed: 29387058
Haematologica. 2021 Apr 01;106(4):987-999
pubmed: 32381575
J Immunother. 2019 Feb/Mar;42(2):33-42
pubmed: 30586347
Cancer Res. 2005 Jun 15;65(12):5238-47
pubmed: 15958569